## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Dunstan et al.

Serial No.:

09/389,782

Filed:

September 3, 1999

For:

**OPG Fusion Protein Compositions and** 

Methods

Docket No.: A-604

Group Art Unit No.: 1643

Examiner:

**Not Assigned** 

## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, DC 20231

Sir:

As a means of complying with the duty of disclosure, applicant submits a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Applicant requests consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

**BEST AVAILABLE COPY** 

Robert B. Winter

Attorney/Agent for Applicant(s) Registration No.: 34,458

Phone: (805) 447-2425

Respectfully submitted,

Date: JANUARY 18, 2000

Please send all future correspondence to: U.S. Patent Operations/ RBW Dept. 430, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1789

**CERTIFICATE OF MAILING** 

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231, on the date appearing below.

<u>1-19-2000</u>

Service as tirst class mail in an envelope addressed to the